Page last updated: 2024-12-06

ciramadol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ciramadol: benzylamine analgesics; structure given in fourth source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44463
CHEMBL ID2104132
CHEBI ID135016
SCHEMBL ID26731
MeSH IDM0069621

Synonyms (28)

Synonym
ciramadol
wy-15705
D03523
63269-31-8
ciramadol (usan/inn)
wy-15,705
CHEBI:135016
3-[(r)-dimethylamino-[(1r,2r)-2-hydroxycyclohexyl]methyl]phenol
ciramadolum
9nq109ow0g ,
ciramadol [usan:inn]
phenol, 3-((dimethylamino)(2-hydroxycyclohexyl)methyl)-, (1r-(1alpha(r*),2alpha))-(-)-
(-)-(1r,2r)-2-((r)-alpha-(dimethylamino)-m-hydroxybenzyl)cyclohexanol
unii-9nq109ow0g
ciramadolum [inn-latin]
wy 15705
CHEMBL2104132
ciramadol [mart.]
(-)-(1r,2r)-2-((r)-.alpha.-(dimethylamino)-m-hydroxybenzyl)cyclohexanol
ciramadol [mi]
ciramadol [usan]
phenol, 3-((dimethylamino)(2-hydroxycyclohexyl)methyl)-, (1r-(1.alpha.(r*),2.alpha.))-(-)-
ciramadol [inn]
SCHEMBL26731
Q5121335
DTXSID601018412
HY-136653
CS-0132849

Research Excerpts

Overview

Ciramadol is a new opioid agonist-antagonist analgesic with low potential for dependency. Oral ciramadols appears to be a safe and highly effective analgesic.

ExcerptReferenceRelevance
"Oral ciramadol appears to be a safe and highly effective analgesic."( Double-blind comparison of the analgesic response to oral ciramadol (WY-15.705) and pentazocine in post-operative pain.
Camu, F, 1981
)
0.96
"Ciramadol is a new opioid agonist-antagonist analgesic with low potential for dependency. "( Comparison of the analgesic efficacy and safety oral ciramadol, codeine, and placebo in patients with chronic cancer pain.
McAdams, J; Stambaugh, JE, 1987
)
1.97

Toxicity

ExcerptReferenceRelevance
" The predominant adverse experiences associated with ciramadol were nausea and drowsiness, which were apparently not dose related."( Comparison of the analgesic efficacy and safety oral ciramadol, codeine, and placebo in patients with chronic cancer pain.
McAdams, J; Stambaugh, JE, 1987
)
0.77

Bioavailability

ExcerptReferenceRelevance
"Eleven healthy volunteers completed a study to compare the relative bioavailability to orally administered ciramadol in a fasting versus postprandial state."( The effect of food on ciramadol bioavailability in normal subjects.
Audet, PR; Chiang, S; Locniskar, A; Maroli, A; Morrison, G,
)
0.66
" The drug is well absorbed but undergoes extensive presystemic metabolism when given by the intragastric route (1 mg/kg) to rhesus monkeys."( Metabolic disposition of ciramadol in rhesus monkeys and rats.
Ruelius, HW; Sisenwine, SF; Tio, CO,
)
0.43

Dosage Studied

ExcerptRelevanceReference
" A valid dose-response curve was obtained for both drugs with no significant deviation from parallelism."( Comparative evaluation of ciramadol (WY-15.705), morphine and placebo for treatment of postoperative pain.
Camu, F; Van den Abeele, G, 1985
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyclohexanolsAn alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.74 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (47.37%)5.53%
Reviews1 (2.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]